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Multiple forms of an inositol polyphosphate 5-phosphatase form
signaling complexes with Shc and Grb2
W.M. Kavanaugh*¶, D.A. Pot*†‡¶, S.M. Chin*, M. Deuter-Reinhard*, A.B. Jefferson§,
F.A. Norris§, F.R. Masiarz*, L.S. Cousens*, P.W. Majerus§ and L.T. Williams*†‡
Background: Shc and Grb2 form a complex in cells in response to growth
factor stimulation and link tyrosine kinases to Ras during the resulting signaling
process. Shc and Grb2 each contain domains that mediate interactions with
other unidentified intracellular proteins. For example, the Shc PTB domain
binds to 130 kDa and 145 kDa tyrosine-phosphorylated proteins in response to
stimulation of cells by growth factors, cytokines and crosslinking of antigen
receptors. The Grb2 SH3 domains bind to an unidentified 116 kDa protein 
in T cells. We have identified three proteins, of 110 kDa, 130 kDa and
145 kDa, as a new family of molecules encoded by the same gene. In vivo
studies show that these proteins form signal transduction complexes with Shc
and with Grb2.
Results: The 130 kDa and 145 kDa tyrosine-phosphorylated proteins that
associate with the Shc PTB domain were purified by conventional
chromatographic methods. Partial peptide and cDNA sequences corresponding
to these proteins, termed SIP-145 and SIP-130 (SIP for signaling inositol
polyphosphate 5-phosphatase), identified them as SH2 domain-containing
products of a single gene and as members of the inositol polyphosphate 5-
phosphatase family. The SIP-130 and SIP-145 proteins and inositol
polyphosphate 5-phosphatase activity associated with Shc in vivo in response
to B-cell activation. By using an independent approach, expression cloning, we
found that the Grb2 SH3 domains bind specifically to SIP-110, a 110 kDa
splice variant of SIP-145 and SIP-130, which lacks the SH2 domain. The SIP
proteins hydrolyzed phosphatidylinositol (3,4,5)-trisphosphate (PtdIns (3,4,5)-
P3) and Ins (1,3,4,5)-P4, but not PtdIns (4,5)-P2 or Ins (1,4,5)-P3.
Conclusions: These findings strongly implicate the inositol polyphosphate 5-
phosphatases in Shc- and Grb2-mediated signal transduction. Furthermore,
SIP-110, SIP-130 and SIP-145 prefer 3-phosphorylated substrates, suggesting
a link to the phosphatidylinositol 3-kinase signaling pathway.
Background
Growth factors stimulate cell growth, differentiation and
a variety of other cellular responses by activating intra-
cellular receptor and non-receptor tyrosine kinases [1–3].
One important consequence of tyrosine phosphorylation
is the creation of binding sites for proteins containing
SH2 and PTB domains that specifically recognize phos-
photyrosine and adjacent amino-acid residues [4]. Thus,
tyrosine phosphorylation serves as a switch for the
assembly of complexes of signaling proteins, within
which regulatory signals are generated. In addition to the
SH2 and PTB domains, the SH3 domains participate in
complex assembly by binding to proline-rich target
sequences present in many signaling proteins [4]. The
identification of novel proteins that bind to the SH2,
PTB and SH3 domains of known signaling molecules has
lead to many important insights into how intracellular
signaling is regulated.
Two of the most important of these proteins involved in
tyrosine kinase signaling are Grb2 and Shc. Shc and Grb2
form a complex in response to growth factor stimulation or
oncogenic transformation [5]. These proteins are thought
to transmit mitogenic signals from receptor and non-recep-
tor tyrosine kinases to Ras, a GTP-binding protein
involved in growth regulation in normal tissues and in
many human tumors [5–7]. Precisely how Shc and Grb2
influence Ras activity is unknown.
Both Shc and Grb2 contain functional domains that
mediate interactions with other proteins. Grb2 contains
two SH3 domains and one SH2 domain [8], whereas Shc
contains one SH2 domain [9] and one PTB domain [10].
In some cases, candidate protein ligands for these
domains have been identified. For example, the Grb2
SH2 domain can bind a phosphorylated tyrosine residue
on Shc [5], and the Grb2 SH3 domains can bind to the
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Ras nucleotide-exchange factor Sos [11–13]. However,
other unidentified proteins also are found in Grb2 and
Shc complexes in vivo [10,14]. For example, in T cells
the Grb2 SH3 domains can associate with either a
116 kDa protein or with Sos [14]. Furthermore, we have
previously reported that proteins of approximately
130 kDa and 145 kDa are tyrosine-phosphorylated and
associate with the PTB domain of Shc in response to
treatment of cells with platelet-derived growth factor
(PDGF), fibroblast growth factor (FGF), leukemia
inhibitory factor or interleukin-6, and in activated T cells
and B cells [10]. These observations strongly suggested
that the 130 kDa and 145 kDa proteins are important
signaling molecules.
We have now taken two independent approaches to iden-
tify these proteins — purification of proteins that associate
with Shc, and expression cloning of proteins that bind to
Grb2. Both approaches yielded molecules belonging to
the inositol polyphosphate 5-phosphatase family. We
found that these proteins are alternative products of the
same gene and are present in different complexes in cells.
Furthermore, the proteins that bind to Shc contain an SH2
domain, and the substrate preferences of these enzymes
suggest a link to the phosphatidylinositol 3-kinase
pathway. These findings define a new family of molecules
involved in Shc- and Grb2-mediated signaling.
Results and discussion
Expression cloning of a gene encoding SIP-110
Expression cloning was used to identify proteins that
interact with the SH3 domains of Grb2. The human Grb2
protein was expressed in Escherichia coli as a GST-fusion
protein containing a consensus phosphorylation sequence
for heart muscle kinase (HMK) [15]. This protein was
purified, radioactively labeled using [32P]ATP and HMK,
and used to screen a human placental lgt11 cDNA expres-
sion library [15]. Because the probe contained both the
SH2 and the SH3 domains of Grb2, we identified clones
that represented autophosphorylated tyrosine kinases that
were bound to the SH2 domain of Grb2. Therefore, dupli-
cate filters were immunoblotted with anti-phosphotyrosine
antibodies to identify and eliminate these SH2 domain-
mediated interactions from consideration. One clone was
identified that interacted with Grb2 and was not tyrosine
phosphorylated. This interaction was specific for Grb2.
Radioactive protein probes that contained the Vav
SH3–SH2–SH3 domains, the Nck SH3–SH3–SH3
domains, or the p85 SH3 domain, did not bind to the
protein encoded by this clone (data not shown).
Sequencing of the full-length 4147 base-pair (bp) clone
identified an open reading frame encoding a novel protein
of 976 amino acids (Fig. 1a). An in-frame stop codon 5′ to
the initiator methionine codon indicated that the cDNA
was complete. The predicted 110 kDa protein contained
proline-rich motifs and had significant homology to a
family of proteins known as inositol polyphosphate 5-
phosphatases [16–20] (Fig. 1b). We have therefore named
the protein SIP-110 (for signaling inositol polyphosphate
5-phosphatase, 110 kDa). A fragment of SIP-110, encoded
by a partial lgt11 clone (Fig. 1a, sequences to the right of
the arrow at position 2679), which contained only the
carboxy-terminal proline-rich sequences, also bound
specifically to Grb2, indicating that the Grb2 binding site
resides in this fragment.
SIP-110 associates with the SH3 domains of Grb2 in cells
To determine whether Grb2 associates with SIP-110 in
vivo, epitope-tagged versions of these molecules were co-
expressed in COS cells. SIP-110 tagged with the hemagglu-
tinin (HA) epitope co-immunoprecipitated with myc-
tagged Grb2, and with Grb2 containing an inactivating
deletion in the SH2 domain, Grb3.3 [21] (Fig. 2, lanes 3 and
7, upper panel; lane 6, lower panel). The interaction
between wild-type Grb2 and SIP-110 was not detectable on
immunoblots probed with the the anti-myc antibody,
because Grb2 co-migrated with immunoglobulin light chain
in these gels. A point mutation in either of the Grb2 SH3
domains markedly reduced or eliminated SIP-110 binding
(Fig. 2, lanes 4 and 5, upper panel). Therefore, Grb2 associ-
ates with SIP-110 in cells. Furthermore, the SH3 domains,
but not the SH2 domain, of Grb2 are necessary for inter-
action with SIP-110. Taken together, these experiments
demonstrate that the SH3 domains of Grb2 bind specifi-
cally to the proline-rich region of SIP-110 in cells.
Purification of proteins that bind the Shc PTB domain
Independently, we purified proteins that associate with the
PTB domain of Shc. We previously reported that proteins
of approximately 145 kDa and 130 kDa are tyrosine-phos-
phorylated and associate with the PTB domain of Shc in
response to treatment of cells with growth factors, and to
antigen receptor crosslinking [10]. These observations
strongly suggested that p145 and p130 are important signal-
ing molecules. We have purified the p145 and p130 pro-
teins from murine BAL 17 B cells stimulated by crosslink-
ing of the B-cell antigen receptor with anti-immunoglobulin
M antibodies. Affinity chromatography with anti-phospho-
tyrosine antibodies was followed by anion exchange chro-
matography and SDS–PAGE. The purification of p145 and
p130 was followed at each step by assaying for proteins that
specifically bound to the Shc PTB domain in a far-western
blot, as described previously [10]. No proteins were found
to bind to the PTB domain in crude extracts from unstimu-
lated B cells (data not shown). In crude extracts from stimu-
lated B cells, two proteins of approximately 130 kDa and
145 kDa bound to the PTB domain [10]. The partially puri-
fied 130 kDa and 145 kDa proteins were excised from a
SDS–PAGE gel and digested with endoproteinase Lys-C.
The peptides were then extracted, purified, and sequenced
according to standard methods.
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Five p145 peptides and three p130 peptides were
sequenced. Surprisingly, four of the p145 peptides and all
three p130 peptides contained sequences identical to the
110 kDa SIP-110 (Fig. 1a). One p145-derived peptide
contained an aspartic acid residue instead of the glutamic
acid at position 839 of SIP-110. One p145-derived peptide
contained unique sequence not found in sequence data-
bases (see below and Fig. 1a). The p130 and p145 pep-
tides were identical to widely separated portions of the
SIP-110 sequence, suggesting that p130, p145 and SIP-
110 are homologous over a large portion of the SIP-110
sequence. These results demonstrated that p130 and p145
have a high degree of similarity to SIP-110, and are likely
to be inositol polyphosphate 5-phosphatases. Further-
more, the presence of unique sequence in p145 and the
difference in molecular weights of SIP-110 and p145 and
p130 demonstrate that they are not the same protein. We
have therefore named these proteins SIP-145 and SIP-130
(for signaling inositol polyphosphate 5-phosphatases of
145 kDa and 130 kDa).
We obtained the SIP-145 cDNAs by probing a human
lung cDNA library with nucleotide sequences correspond-
ing to SIP-110. A 3537 bp partial cDNA of SIP-145 was
obtained with an open reading frame of 1178 amino acids
(Fig. 1a). The predicted amino-acid sequence of this
cDNA contained all of the peptide sequences isolated
from the purified p145 and p130 proteins (Fig. 1a). In one
p145-derived peptide, four out of eighteen residues
differed from the corresponding predicted amino-acid
sequence deduced from the SIP-145 cDNA. Three of
these residues represented conservative substitutions.
This probably reflects species differences between the
peptide, which was derived from mouse p145 protein, and
the cDNA encoding SIP-145, which was obtained from a
human cDNA library.
Nucleotides 788–3537 of the SIP-145 partial cDNA were
identical to nucleotides 37–2786 of SIP-110 (Fig. 1a). This
suggested that SIP-110 is a splice variant of SIP-145 which
lacks the amino-terminal region of SIP-145. The presence
of at least two bands on a northern blot probed with SIP-
110 DNA supported this idea (data not shown). Further-
more, an in-frame ATG codon between nucleotides
122–124 of the SIP-145 cDNA was flanked by a consensus
translation initiation sequence [22]. Translation beginning
at this site would produce a protein of approximate pre-
dicted molecular weight of 133 kDa, suggesting that the
translation of SIP-130 is initiated at an internal ATG
within the SIP-145 mRNA.
The predicted amino-acid sequence of SIP-145 contained
an SH2 domain in the amino-terminal region which
would be predicted to be present in SIP-130, but is not
present in the SIP-110 cDNA (Fig. 1a,b). The 3′ end of
the SIP-145 cDNA is identical to SIP-110, and therefore
contains several of the proline-rich sequences present in
the carboxyl terminus of SIP-110. Because the SIP-145
cDNA was incomplete at the 3′ end, we cannot yet deter-
mine if the SIP-145 and SIP-110 are completely identical
Figure 1 (part (a) is on facing page)
Sequence analysis of SIP-110, SIP-130 and
SIP-145, and comparison with inositol
polyphosphate 5-phosphatases. (a) cDNA
and predicted amino-acid sequences of SIP-
110 (GenBank accession number U50040)
and a partial SIP-145 clone (GenBank
accession number U50041). The sequences
that are present in SIP-145 but not in SIP-110
are italicized and are numbered separately
from the full-length SIP-110 cDNA. The
junction between the SIP-145 and SIP-110
sequences is indicated by the large arrow.
The putative internal translation start site for
SIP-130 is indicated by a box. The predicted
amino-acid sequences of SIP-145 and SIP-
110 are compared with peptide sequences
obtained from purified p145 (bold italics) and
p130 (bold type) proteins; X denotes an
undetermined residue. The in-frame stop
codon 5′ to SIP-110 ATG is in bold type.
Proline-rich SH3-binding motifs are indicated
by bold underlined italics. The sequence of
the partial lgt11 clone of SIP-110 which
binds to Grb2 (see text) begins at nucleotide
2679 of the full-length SIP-110 (arrow). The
SH2 domain of SIP-145 is underlined.
Asterisks denote the conserved sequence
motifs that define the inositol polyphosphate
5-phosphatase family [24]. (b) Homology
between SIP-110, SIP-130 and SIP-145 and
other inositol polyphosphate 5-phosphatases.
SIP amino-acid sequences were compared to
OCRL1 (the protein defective in Lowe’s
oculocerebrorenal syndrome) [16], type II
inositol polyphosphate 5-phosphatase
(5Ptase II) [24], INPPL1 [18] and synapto-
janin [42]. Percent identity and similarity
(parentheses) for the indicated regions are
shown. Black boxes indicate the position of
the conserved inositol polyphosphate 5-
phosphatase sequence motifs (see asterisks
in (a)). The asterisk in synaptojanin indicates
the stop codon for the 145 kDa form.
SIP-145
SIP-130
SIP-110
INPPL1
Synaptojanin
5Ptase Il
OCRL1
SH2
SH2
*
100 amino acids
24 (48)
19 (41)
18 (42)
36 (57)
37 (58)
37 (66)
44 (65)
19 (40)
17 (41)
23 (41)
28 (50)64 (81)
(b)
in this region. However, the presence of both a SH2
domain and proline-rich sequences in the SIP-145
sequence strongly implicate SIP-145 as an important
signaling molecule.
SIP-130 and SIP-145 associate with Shc in vivo in response
to B-cell activation
The 110 kDa, 130 kDa and 145 kDa SIPs were found to
be present in different complexes in cells. Antibodies
were raised against three different epitopes of SIP-110. In
lysates (data not shown) and in anti-SIP-110 immuno-
precipitates (Fig. 3a) from B-cell extracts these antibodies
recognized SIP-110, as well as SIP-130 and SIP-145. Shc
immunoprecipitates from unstimulated and stimulated
BAL 17 cells were analyzed by immunoblotting with
these anti-SIP-110 antibodies.  All three anti-SIP-110 anti-
bodies specifically recognized proteins of 130 and 145 kDa
in Shc immunoprecipitates from stimulated cells, but not
in immunoprecipitates from unstimulated cells or in pre-
immune immunoprecipitates (Fig. 3b). Taken together,
these data demonstrate that the 130 kDa and 145 kDa
proteins that were purified are structurally and immuno-
logically similar, but not identical, to SIP-110. Further-
more, the interaction of SIP-130 and SIP-145 with Shc is
likely to be important, because SIP-130 and SIP-145 bind
Shc only in response to stimulation of cells. SIP-110 was
not detected in Shc immunoprecipitates (Fig. 3b), despite
the presence of SIP-110 in anti-SIP-110 immunoprecipi-
tates (Fig. 3a). These data suggest that SIP-110 does not
form a stable complex with Shc.
Inositol polyphosphate 5-phosphatase activities of SIP-
110, SIP-130 and SIP-145.
We next analyzed the enzymatic activity of SIP-110, SIP-
130 and SIP-145. Inositol polyphosphate 5-phosphatases
442 Current Biology 1996, Vol 6 No 4
Figure 3
(a) Immunoblotting of SIP-110, SIP-130 and
SIP-145. Proteins were immunoprecipitated
from B-cell extracts with pre-immune sera, or
the anti-SIP-110 antisera DP3, and
immunoblotted with the anti-SIP-110 antisera
8727. The positions of SIP-110, SIP-130 and
SIP-145 are indicated. (b) SIP-130 and SIP-
145 specifically associate with Shc in
response to B-cell activation in vivo. Pre-
immune and anti-Shc immunoprecipitates
from unstimulated and activated B cells were
immunoblotted with two different antibodies
raised against separate epitopes of SIP-110
(DP3, left panel; DP5, right panel). The
positions of SIP-130 and SIP-145 are
indicated by arrows: these bands were absent
when immunoblotting was carried out using
pre-immune sera (data not shown).
205
121
86
51
205
121
86
51
SIP-145 SIP-145
SIP-130
SIP-110
SIP-130
An
ti-S
IP-
11
0 (
DP
3)
Pre
-im
mu
ne
Immunoprecipitation:
Anti-SIP-110 (8727) Anti-SIP-110 (DP3) Anti-SIP-110 (DP5)Blot:Blot:
– + – + – + – +Stimulation:
Immunoprecipitation: Pre Anti-Shc Pre Anti-Shc
(a) (b)
Figure 2
SIP-110 associates with the SH3 domains of Grb2 in COS cells.
COS7 cells were transiently co-transfected with SIP-110 tagged
with the HA epitope and with the following derivatives of Grb2
tagged with the myc epitope: wild-type Grb2 (Grb2 wt), Grb3.3
(containing an inactivating deletion in the SH2 domain), and Grb2
P49L and G203R (containing inactivating point mutations in each of
the SH3 domains). Cell lysates were immunoprecipitated with the
anti-myc antibody 9E10 (lanes 1, 3, 4, 5 and 7) or the anti-HA
antibody 12CA5 (lanes 2 and 6) and immunoblotted with the same
anti-HA (upper panel) and anti-myc (lower panel) antibodies. ‘Mock’
represents the untransfected COS cell background in anti-myc
immunoprecipitates. Grb2 migrates with immunoglobulin light chain
and is obscured in these gels, whereas the smaller Grb3.3 migrates
slightly faster and can be identified (lane 6, lower panel).
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hydrolyze the 5-phosphate from inositol (1,4,5) trisphos-
phate (Ins(1,4,5)-P3) and Ins(1,3,4,5)-P4 [17,19,20,23,24].
A subset of these enzymes can remove the 5-phosphate
from phosphatidylinositol (PtdIns) polyphosphates
[23–26]. Recombinant SIP-110 hydrolyzed PtdIns (3,4,5)-
P3 to PtdIns (3,4)-P2, as did a different member of this
family of enzymes, 5Ptase II [24] (Fig. 4a). The product of
this reaction was shown to be PtdIns (3,4)-P2 by incubat-
ing the product with purified inositol 4-phosphatase,
which generated radioactive PtdIns (3)-P (data not shown,
and [27]). SIP-110 also hydrolyzed Ins (1,3,4,5)-P4 to 
Ins (1,3,4)-P3 with a Km of 15.7 mM and Vmax of
100 nmol min–1 mg–1. The product of this reaction was Ins
(1,3,4)-P3, because it could be further converted to an Ins-
P2 by purified inositol polyphosphate 1- or 4-phosphatase,
neither of which hydrolyze Ins (1,4,5)-P3 [28,29].
Immunoprecipitation of baculovirus-expressed HA-tagged
SIP-110 with anti-HA antibodies also shifted the Ins-P4-
hydrolyzing activity from the supernatant to the protein
A–Sepharose pellet (data not shown). This clearly demon-
strates that the hydrolyzing activity resides in the SIP-110
protein. The substrate specificity of SIP-110 is different
from that of 5Ptase II because SIP-110 did not hydrolyze
Ins (1,4,5)-P3 or PtdIns (4,5)-P2, both of which are excel-
lent substrates for 5Ptase II (data not shown). Therefore,
SIP-110 is an unique inositol and phosphatidylinositol
polyphosphate 5-phosphatase which prefers substrates
phosphorylated at the 3 position. Because the activity of
phosphatidylinositol 3-kinase on PtdIns (4,5)-P2 would
create an ideal substrate for SIP-110, it is possible that
these enzymes act sequentially.
To determine whether SIP-130 and SIP-145 are also func-
tional phosphatidylinositol or inositol polyphosphate phos-
phatases, anti-Shc immunoprecipitates were assayed for
their ability to hydrolyze inositol polyphosphates. An
activity that hydrolyzed Ins (1,3,4,5)-P4 was detected in
immunoprecipitates of Shc from activated B cells but not
in immunoprecipitates from unstimulated cells, or in pre-
immune immunoprecipitates (Fig. 4b). No hydrolysis of
Ins (1,4,5)-P3 over background was detected in any of
these samples. Further, Shc immunoprecipitates from
activated B-cell lysates contained an activity that
hydrolyzed PtdIns (3,4,5)-P3 to PtdIns-P2 (data not
shown). This activity was not observed in Shc immuno-
precipitates from unstimulated lysates or in pre-immune
immunoprecipitates. Therefore, PtdIns (3,4,5)-P3 and Ins
(1,3,4,5)-P4 5-phosphatase activities specifically associate
with Shc in response to B-cell activation. Like SIP-110,
these activities exhibit a preference for 3-phosphorylated
substrates. This activity is unlikely to be due to the pres-
ence of SIP-110, as no 110 kDa protein was detected in
these immunoprecipitates when immunoblotted with
anti-SIP-110 antibodies, despite the presence of easily
detected SIP-110 in lysates from these cells (Fig. 3).
Therefore, one or both of SIP-130 and SIP-145 are also
functional inositol polyphosphate phosphatases with a
preference for 3-phosphorylated substrates. 
Conclusions
These results strongly implicate the inositol polyphos-
phate 5-phosphatases in Shc- and Grb2-mediated signal
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Figure 4
Enzymatic activity of SIP-110, SIP-130 and SIP-145. (a) Time course
of hydrolysis of PtdIns (3,4,5)-P3 by SIP-110 and 5Ptase II. Production
of [32P]PtdIns-P2 from [32P]PtdIns(3,4,5)-P3 is plotted as a function of
time. Each point is the average of quadruplicate assays. The inset
shows an autoradiogram of a thin layer chromatographic (TLC) plate
showing conversion of [32P]PtdIns(3,4,5)-P3 to [32P]PtdIns-P2 by SIP-
110 and 5Ptase II. (b) Association of Ins (1,3,4,5)-P4 phosphatase
activity with Shc in response to B-cell activation. Extracts from
unstimulated B cells (–) or activated B cells (+) were
immunoprecipitated with pre-immune sera or antibodies to Shc (Shc)
and assayed for hydrolysis of [3H]Ins(1,3,4,5)-P4 (gray bars) or [3H]-
Ins(1,4,5)-P3 (white bars). Results are expressed as pmoles of
hydrolysis product per 30 min per immunoprecipitate. A blank sample
containing no proteins was assayed and subtracted as background. A
representative experiment is shown.
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transduction. Three different members of this family of
proteins were identified by independent methods to bind
to Shc or to Grb2. The three proteins are likely to be
products of the same gene. The data are consistent with a
model in which activation of tyrosine kinases in cells
leads to tyrosine phosphorylation of SIP-130 and SIP-145,
which then bind to the PTB domain of Shc. The identifi-
cation of a related 110 kDa inositol polyphosphate
5-phosphatase which binds to the SH3 domains of Grb2
identifies the inositol polyphosphate 5-phosphatases as a
new family of molecules involved in tyrosine kinase
signaling. The importance of inositol polyphosphate
5-phosphatases in signaling is strongly suggested by the
finding that two signaling molecules known to be impor-
tant in mediating signaling from tyrosine kinases, Shc and
Grb2, bind to similar but distinct inositol polyphosphate
5-phosphatases. Furthermore, SIP-130 and SIP-145
contain a SH2 domain, and are therefore likely to associ-
ate with other tyrosine-phosphorylated protein(s).
Finally, the preference of these enzymes for inositol sub-
strates phosphorylated at the 3- position suggests that
signaling through Shc, Grb2 and phosphatidylinositol
3-kinase are linked. The observation that Shc, Grb2 and
phosphatidylinositol-3 kinase can all  signal through Ras
[5–7,30] suggests that the inositol polyphosphate 5-phos-
phatases act within a signaling complex to effect Ras-
dependent signaling pathways.
Materials and methods
Expression cloning of SIP-110
Human Grb2 cDNA was obtained by screening a human placental
library with the sem5 cDNA of Caenorhabditis elegans (a gift from M.
Stern, Yale University). Grb2 was expressed in bacteria using pGexKT
[31], with the HMK phosphorylation sequence inserted between GST
and Grb2. The protein was purified by glutathione–agarose affinity
chromatography and labeled with [32P]ATP and HMK to a specific
activity of 1 × 107 [32PO4] cpm per mg Grb2 as described [10,15]. The
radioactively labeled protein was used to screen a Clonetech oligo dT-
primed human placental cDNA expression library [15]. A full-length
cDNA clone encoding SIP-110 was obtained by screening a lgt10
human placental cDNA library with the DNA of the original clone (Fig.
1, arrow at position 2679) [32]. Radioactive protein probes were pre-
pared from Vav (amino acids 648–844 [33]), Nck (amino acids 1–149
[34]), and the 85 kDa subunit of phosphatidylinositol 3-kinase (amino
acids 1–81 [35]) in a similar manner, and used to test binding to a puri-
fied SIP-110-expressing phage under conditions identical to the
screening.
Expression of SIP-110 and Grb2 variants in cells
COS7 cells were transiently transfected by the method of Gorman
[36]. Full-length SIP-110 with an amino-terminal HA epitope was
expressed from the plasmid pCG [37]. Full-length Grb2 was expressed
from pCG with a Myc epitope at its carboxyl terminus. Grb3.3, which
contains an inactivating deletion in its SH2 domain[21] and a carboxy-
terminal Myc epitope tag was generated by PCR and cloned into pCG.
Grb2 variants, containing inactivating point mutations in the SH3
domains (human counterparts of natural C. elegans Sem-5 mutations
[8,38]) and a carboxy-terminal Myc epitope tag were also generated by
PCR and cloned into pCG. Baculovirus–SIP-110 generated from the
plasmid pV-IKS [10] was expressed in Sf9 cells and lysates assayed
for inositol polyphosphate 5-phosphatase activity as described below.
Purification of proteins binding to the Shc PTB domain 
The p130 and p145 proteins were purified from extracts of BAL 17 B
cells stimulated by crosslinking the antigen receptor with anti-
immunoglobulin M antibodies as described [39]. Briefly, viable cells
were resuspended to 1 × 108 cells ml–1 in PBS, incubated at 37 °C for
5 min, sodium orthovanadate was added to 250 mM, and the cells incu-
bated another 5 min at 37 °C. Anti-IgM immunoglobulin (Jackson
ImmunoResearch) was added to 1.0 mg per 109 cells for 2 min at
37 °C, the slurry was diluted immediately in ice-cold PBS and cen-
trifuged at 4500 × g at 4 °C for 5 min. Cell pellets were Dounce homog-
enized in 20 mM Tris (pH 8.0), 0.5 mM vanadate, and protease
inhibitors. The supernatants were loaded at 0.8 ml min–1 onto a 15 ml
(1.0 cm × 1.3 cm) anti-phosphotyrosine antibody affinity column and
eluted at 0.13 ml min–1 in the same buffer containing 100 mM
phenylphosphate. Column fractions (0.5 ml) were assayed for the p130
and p145 PTB domain-binding proteins as described [10]. Briefly,
aliquots of each fraction were analyzed by SDS–PAGE, transferred to
nitrocellulose and incubated with 32P-labeled Shc PTB domain protein
as a probe. The filters were then washed and exposed to X-ray film.
Fractions containing p130 and p145 were then dialyzed against 20 mM
Tris–HCl (pH 7.5), 2 mM Na Tungstate, 2 mM Na Arsenate, 1 mM ben-
zamidine and 1 mM DTT, loaded at 1 ml min–1 onto a 5 ml Pharmacia Q
FF anion exchange column, and eluted with a 100 ml, 0 to 1 M NaCl
gradient (1 ml min–1). Peak fractions (2 ml each) eluted in a broad peak
between approximately 260 and 330 mM NaCl. These were pooled and
analyzed by SDS–PAGE. The 130 kDa and 145 kDa bands were then
excised from the gel, digested in situ with endoproteinase Lys-C, the
peptides purified by HPLC, and sequenced by standard methods [40].
Approximately 50 pmoles of p145 was purified from 4.4× 1011 cells.
Immunoprecipitations and immunoblotting
BAL 17 cells were stimulated and lysed as described [10,39]. Rabbit
antisera was raised against SIP-110 residues 48–231 (antibody DP3),
residues 232–500 (antibody DP5) and residues 891–976 (antibody
8727) and against Shc residues 366–473. Immunoprecipitations and
immunoblotting were performed as described [10].
Enzyme assays
[32P]PtdIns (3,4,5)-P3 was prepared as described [27] using PtdIns
(4,5)-P2 and recombinant phosphatidylinositol 3-kinase [30]. TLC-puri-
fied [32P]PtdIns (3,4,5)-P3 (84 000 cpm) was evaporated under nitro-
gen with 600 mg phosphatidylserine and resuspended into vesicles.
Reaction mixtures (25 ml) contained 20 ng baculovirus-expressed
recombinant SIP-110 or 31 ng recombinant 5-ptase II [24], 1400 cpm
[32P]PtdIns (3,4,5)-P3, 50 mM Tris (pH 7.5) and 10 mM MgCl2, and
were incubated at 37 °C for 1, 3 or 10 min. Hydrolysis was determined
as described [27]. Hydrolysis of [3H]Ins (1,3,4,5)-P4 and [3H]Ins
(1,4,5)-P3 was measured as described [41].
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